Medical Packaging Manufacturing in the Dominican Republic: FDA Compliance and Export Guide

Medical packaging — the sterile barrier systems, blister packs, pouches, trays, and folding cartons that protect medical devices and pharmaceutical products from contamination and damage — is one of the highest-value and fastest-growing segments of Dominican Republic free zone manufacturing. US medical device and pharmaceutical companies that manufacture in the DR have an aligned interest in sourcing packaging locally: it reduces logistics complexity, improves supply chain integration, and leverages the same CAFTA-DR zero-tariff framework that governs their finished goods exports.

This guide covers the FDA compliance requirements for medical packaging manufactured in the Dominican Republic, the ISO 11607 certification framework for sterile barrier systems, key manufacturing capabilities available in the DR, and the commercial and regulatory considerations for US companies establishing or expanding medical packaging supply relationships in the Caribbean Economic Corridor.

FDA Regulatory Framework for Medical Packaging

Medical device packaging manufactured in the Dominican Republic for the US market is subject to FDA jurisdiction under 21 CFR Part 820 (Quality System Regulation) as a component of the finished medical device. Packaging facilities supplying US medical device manufacturers must comply with the device manufacturer’s quality system requirements, which flow down FDA regulatory obligations to the packaging supplier through supplier qualification and control procedures.

For pharmaceutical packaging (blister packs, foil packaging, bottles, closures for drug products), FDA 21 CFR 211 requirements apply, including container closure system suitability testing, extractables and leachables assessment for drug-contact packaging materials, and stability compatibility validation. Dominican facilities that have established extractables/leachables testing capabilities or partnerships with accredited US testing laboratories are better positioned for pharmaceutical packaging client qualifications.

ISO 11607 Certification in DR Facilities

ISO 11607 Part 2 validation — covering seal integrity, package integrity, and sterile barrier system performance — requires documented validation protocols including Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) for all sealing and forming equipment. DR medical packaging facilities that have completed ISO 11607 validation typically maintain qualification documentation packages that US medical device client quality teams can review during supplier qualification audits, significantly reducing the client-side qualification timeline.

Supply Chain Integration for Medical OEMs in DR

US medical device OEMs operating DR manufacturing facilities benefit most from co-locating packaging supply within the same free zone corridor — either through an on-site packaging supplier or a packaging partner in the same park. This co-location eliminates the international import duties and logistics complexity that separate-country packaging sourcing creates, while maintaining the same CAFTA-DR regulatory and incentive framework. Several DR free zone parks have developed medical manufacturing clusters specifically designed to accommodate co-located device manufacturing and packaging supply relationships.

Frequently Asked Questions

Can a Dominican packaging facility appear on a US medical device 510(k) or PMA as a component manufacturer?

Yes. A Dominican Republic packaging facility registered with FDA and included in the device manufacturer’s quality system as a controlled supplier can be identified as a component manufacturer in 510(k) or PMA submissions. The device manufacturer retains primary FDA regulatory responsibility; the packaging supplier is documented as part of the design history file and production record system. FDA inspections may include review of supplier control procedures and may request packaging facility audit records.

What are extractables and leachables, and do DR pharmaceutical packaging facilities test for them?

Extractables are chemical compounds that can be released from packaging materials under controlled laboratory conditions; leachables are compounds that migrate into drug products under normal conditions of use. FDA requires extractables/leachables (E&L) assessment for container closure systems for injectable, inhalation, ophthalmic, and oral liquid drug products. DR pharmaceutical packaging facilities with E&L capability are limited; most DR-based packaging companies partner with accredited US or European E&L testing laboratories. The packaging manufacturer provides material composition and extraction data; the testing laboratory performs the actual E&L analysis.

How does EGS support medical packaging supply chain development in the DR corridor?

EGS connects US medical device and pharmaceutical companies with qualified Dominican medical packaging suppliers through the Caribbean Economic Corridor supply chain development framework. For US companies seeking to qualify DR-based packaging supply, EGS provides supplier identification, qualification support coordination, and regulatory navigation assistance through its CNZFE and PROINVERSION institutional relationships. This reduces the time and cost of supplier qualification versus independent market entry.

Explore More: EGS Insights Hub | DR Manufacturing Sectors | Contact Our Team